Skip to main content
ALGORAE PHARMACEUTICALS LIMITED logo

ALGORAE PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · 1AI ISIN · AU0000296022 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,159 across all filing types
Latest filing 2026-05-24 Share Issue/Capital Cha…
Country AU Australia
Listing ASX 1AI

About ALGORAE PHARMACEUTICALS LIMITED

https://algoraepharma.com/

Algorae Pharmaceuticals Limited is a biopharmaceutical company focused on the discovery and development of novel therapeutic solutions for complex medical conditions. The company leverages its proprietary artificial intelligence platform, AlgoraeOS, to streamline the drug discovery process and identify synergistic drug combinations. Its research pipeline primarily targets neurodegenerative diseases and other areas of high unmet clinical need. Key development programs include AI-116, a combination therapy aimed at treating dementia and Alzheimer's disease. By integrating advanced computational modeling with traditional pharmacological research, the company seeks to accelerate the transition of candidates from preclinical stages to clinical trials, optimizing therapeutic efficacy and safety profiles.

Recent filings

Filing Released Lang Actions
Application for quotation of securities - 1AI 7 pages 20.8KB
Share Issue/Capital Change Classification · 92% confidence The document is the ASX Appendix 2A “Application for quotation of securities” detailing the issuance and quotation of 500,000 new shares under an employee incentive plan. This is a capital change announcement (new share issue/quotation) rather than a full financial report or regulatory certification. It fits the Share Issue/Capital Change category.
2026-05-24 English
Notification regarding unquoted securities - 1AI 6 pages 18.4KB
Share Issue/Capital Change Classification · 97% confidence The document is an ASX Appendix 3G notification of the issue/conversion of unquoted equity securities (performance rights) under an employee incentive scheme. It details the number of securities issued, dates, and listing rule references. This is clearly an announcement of a share issuance/capital change, matching the definition for Share Issue/Capital Change (Code: SHA).
2026-05-24 English
Algorae Expands AI Drug Combination Pipeline 3 pages 162.3KB
Regulatory Filings Classification · 82% confidence The document is an ASX announcement providing operational and scientific updates on Algorae’s AI drug combination program. It does not contain financial statements, earnings figures, dividend details, or request shareholder action, nor is it an investor presentation deck or standalone annual/interim report. Rather, it is a general regulatory/market announcement of corporate progress. This fits the fallback category for miscellaneous regulatory releases.
2026-05-17 English
1AI Executes License & Supply Agreement with Torrent Pharma 3 pages 163.6KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 6 May 2026 from Algorae Pharmaceuticals regarding the execution of a Licence & Supply Agreement with Torrent Pharmaceuticals. It details the terms of the agreement, phased commercialisation strategy, roles and responsibilities, and background information about both companies. The document is a corporate announcement about a commercial agreement and future business plans, without any financial statements, earnings data, or regulatory filings. It does not contain financial results, audit information, management changes, or voting results. It is not a report but a business update announcement. Therefore, the most appropriate classification is Capital/Financing Update (CAP), as it relates to a commercial agreement impacting the company's business and potential revenue generation.
2026-05-05 English
Quarterly Activities Report /Appendix 4C Cash Flow Statement 11 pages 1.1MB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'MARCH 2026 QUARTERLY ACTIVITIES REPORT & APPENDIX 4C' and provides detailed financial and operational updates for the quarter ended 31 March 2026. It includes financial position data, cash reserves, financing inflows, commercial agreements, R&D activities, board and leadership changes, and a financial overview with cash flow details. The content is comprehensive and substantive, containing actual financial data and analysis for a period shorter than a full fiscal year (a quarter). This matches the definition of an Interim / Quarterly Report (IR). The document is not merely an announcement or a brief summary but a full quarterly report with detailed information. Therefore, the correct classification is IR with high confidence.
2026-04-29 English
Algorae and Zydus Enter Exclusive Commercial Agreement 3 pages 155.0KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 28 April 2026 from Algorae Pharmaceuticals regarding a new exclusive commercial and licensing agreement with Zydus Lifesciences for 10 products in the Australia and New Zealand markets. The content focuses on the details of the commercial agreement, strategic collaboration, and company statements about the partnership. There are no financial statements, quarterly or annual results, nor any regulatory filings or voting results. The document is a corporate announcement about a commercial agreement and partnership, which fits best under Capital/Financing Update (CAP) as it relates to company financing and commercial activities rather than a financial report or other categories. The document length is 7535 characters, which is substantive and not a mere announcement of a report publication. Therefore, the classification is Capital/Financing Update (CAP) with high confidence.
2026-04-27 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.